Analyst Ratings for AbCellera Biologics (ABCL)
ABCL Rating Summary
ABCL Price Target Summary
- Highest: $30.00 (Truist Securities)
- Lowest: $4.00 (Leerink)
- Average: $13.29
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$13.29 (+14.8%)
* Over Last 12-Mos
Rating Score: 9.2 / 10
Percentile Rank: 90%
Avg. $ Target:
$13.29 (+14.8%)
* Over Last 12-Mos
Rating Score: 9.2 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/7/2026 | StoneX | Robert Wasserman | Upgrade | Buy (Hold) |
11.00 (N/A) |
7.87 (11.57) |
47.01% | Details |
| 5/5/2026 | Cantor Fitzgerald » Updated 7/17/2026 |
Steve Seedhouse | New Coverage | Overweight (N/A) |
11.00 (11.00) |
4.59 (11.57) |
152.07% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
